These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37577663)

  • 21. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
    Sharma A; Rani R
    J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
    Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined PI3K and MAPK inhibition synergizes to suppress PDAC.
    Bye BA; Jack J; Pierce A; Walsh RM; Eades A; Chalise P; Olou A; VanSaun MN
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models.
    Seidel D; Rothe R; Kirsten M; Jahnke HG; Dumann K; Ziemer M; Simon JC; Robitzki AA
    Biosens Bioelectron; 2019 Jan; 123():185-194. PubMed ID: 30201332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer.
    Chen J; Dai J; Kang Z; Yang T; Zhao Q; Zheng J; Zhang X; Zhang J; Xu J; Sun G; Yang L; Yang T
    Exp Cell Res; 2020 Aug; 393(1):112060. PubMed ID: 32407729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
    Lee J; Liu H; Pearson T; Iwase T; Fuson J; Lalani AS; Eli LD; Diala I; Tripathy D; Lim B; Ueno NT
    Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34203351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
    Sakai T
    Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
    Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
    J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.
    Close DA; Kirkwood JM; Fecek RJ; Storkus WJ; Johnston PA
    SLAS Discov; 2021 Jun; 26(5):712-729. PubMed ID: 33208016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
    Duncan JS; Whittle MC; Nakamura K; Abell AN; Midland AA; Zawistowski JS; Johnson NL; Granger DA; Jordan NV; Darr DB; Usary J; Kuan PF; Smalley DM; Major B; He X; Hoadley KA; Zhou B; Sharpless NE; Perou CM; Kim WY; Gomez SM; Chen X; Jin J; Frye SV; Earp HS; Graves LM; Johnson GL
    Cell; 2012 Apr; 149(2):307-21. PubMed ID: 22500798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
    PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.
    Liu S; Zou Q; Chen JP; Yao X; Guan P; Liang W; Deng P; Lai X; Yin J; Chen J; Chen R; Yu Z; Xiao R; Sun Y; Hong JH; Liu H; Lu H; Chen J; Bei JX; Koh J; Chan JY; Wang B; Kang T; Yu Q; Teh BT; Liu J; Xiong Y; Tan J
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in
    Ghosh S; Fan F; Powell R; Park Y; Stephan C; Kopetz ES; Ellis LM; Bhattacharya R
    bioRxiv; 2024 Sep; ():. PubMed ID: 39282351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.
    Preto AJ; Matos-Filipe P; Mourão J; Moreira IS
    Gigascience; 2022 Sep; 11():. PubMed ID: 36155782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification.
    Lieshout R; Faria AVS; Peppelenbosch MP; van der Laan LJW; Verstegen MMA; Fuhler GM
    Mol Med; 2022 Jun; 28(1):74. PubMed ID: 35764936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.